Discontinued — last reported Q2 '18
Other
Fair Value Measurement Disclosure
Biogen Fair Value Measurement Disclosure increased by 8.3% to $266.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 48.9%, from $522.40M to $266.90M.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryRisk
SignalContext dependent
VolatilityModerate
First reportedQ3 2015
Last reportedQ2 2018
How to read this metric
Changes in this value reflect market volatility impacting the company's portfolio or changes in the composition of assets held at fair value.
Detailed definition
This metric aggregates the carrying amounts of assets and liabilities that are measured at fair value on a recurring or...
Peer comparison
Standardized across industries under GAAP/IFRS fair value hierarchy disclosures.
Metric ID:
fair_value_measurement_disclosureHistorical Data
9 periods
| Q4 '23 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $508.90M | $512.80M | $522.40M | $534.90M | $391.20M | $246.40M | $266.90M |
| QoQ Change | — | — | — | +0.8% | +1.9% | +2.4% | -26.9% | -37.0% | +8.3% |
| YoY Change | — | — | — | — | — | — | -23.1% | -52.0% | -48.9% |
Range$0.00 – $534.90M
Avg YoY Growth-41.3%
Median YoY Growth-48.9%
Fair Value Measurement Disclosure at Other Companies
Frequently Asked Questions
- What is Biogen's fair value measurement disclosure?
- Biogen (BIIB) reported fair value measurement disclosure of $266.90M in Q1 2026.
- How has Biogen's fair value measurement disclosure changed year-over-year?
- Biogen's fair value measurement disclosure decreased by 48.9% year-over-year, from $522.40M to $266.90M.
- What does fair value measurement disclosure mean?
- The total value of assets and liabilities that are reported at their current market price rather than historical cost.